MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
Shelize Khakoo(Royal Marsden NHS Foundation Trust), David Cunningham(Royal Marsden NHS Foundation Trust), Ian Chau(Royal Marsden NHS Foundation Trust), Thomas R. Jones(University of New Mexico), Michael Hubank(Royal Marsden Hospital), Monica Terlizzo(Royal Marsden NHS Foundation Trust), Eleftheria Kalaitzaki(University College London), Katharina von Loga, Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Claire Saffery(Royal Marsden NHS Foundation Trust), David Watkins, Nicola Valeri(Royal Marsden NHS Foundation Trust), Paul Carter(Royal Marsden NHS Foundation Trust), Gina Brown(Imperial College Healthcare NHS Trust), Ruwaida Begum, Andrew Wotherspoon(Université Libre de Bruxelles), Diana Tait(Royal Marsden NHS Foundation Trust), Ridwan Shaikh(Royal Marsden NHS Foundation Trust), Simona Picchia(Royal Marsden NHS Foundation Trust), Isma Rana(Royal Marsden NHS Foundation Trust), Naureen Starling(Royal Marsden NHS Foundation Trust)
Cited by 138
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k